Stage of development
-
- Molecule
- PNB-001
- Indication
- Dementia
- Biological action
- CCK-mediated release of acetylcholine (ACh)
- Status
- Phase 2 ready
- Background about target
Ach is the key neurotransmitter in learning and memory and in Dementia, such as Alzheimer’s Disease Ach esterase inhibitors are approved agents.
Ach inhibitors prolong the action of Ach by reducing its degration. CCK agonists, such as CCK8s and PNB001 at low concentrations trigger the release of Ach and therefore, improve learning and memory in rodents and clinically in Dementia patients.
Ach is stimulating lymphocytes, trigger the release of insulin via the M3 receptor and enhance leaning and memory via nicotinic action, but ACH blocker scopolamine is impairing the memory function in rats and human.
- Introduction of treatment options
The new developments towards tau protein targets are very expensive and provide only very marginal benefits. Best agents are ACH esterase inhibitors and PNB-001 is improving this gold standard of treatment further.
- Preclinical studies:
PNB-001 is developed as novel chemical entity to address the therapeutic area of learning and memory. Extensive studies using the water maze as best in vivo model showed outstanding results. Nicotine served as standard and the PNB-001 action is superior to nicotine and was found of prolonged action. Scopolamine antagonised the effect of PNB-001 and esterase inhibitors, such as Tonizep (Donepezil) enhanced the cognitive action significantly.
Dose limiting factor with donepezil was a slow heart rate and here the Ach release is selectively triggered in the brain and no cardiotoxicity was seen. Interestingly, the cognitive action was maintained over hours irrespective of the PNB-001 short half live and expected action. A bell shaped dose response curve was determined for the biological effect effect with a maximum at 3 mg/kg and a linear range from 0.3-1-2mg/kg. At higher doses, the anticognitive effect is reduced for the right part of the bell-shaped curve. The anti-inflammatory effect is in the 10-20 mg/kg range.
PNB-001 acted as non-classical incretin, a first small molecule non-peptidal incretin, which is proposed to be beneficial in Dementia (Diabetes of the brain). PNB-001 has ex-vivo action, which is CCK based and antagonized by lorglumide and indirect Ach mediated action of the isolated intestine preparation, which is partly blocked by atropine. Averall, the dual direct CCK and indirect ACH modulation effects are the chief MOA for learning and memory in rodents.
- Preclinical development studies:
PNB-001 had a half-life of 1.9 hrs and had a relatively low bioavailability. PNB-001 was evaluated in various ADME studies, including cytochrome P450 enzyme inhibition, plasma protein binding, and CaCo2 permeability. PNB-001 did not inhibit Cyp3A4, Cyp2C9, and Cyp1A2 up to 10 µM and Cyp2C19 until 3 µM. With 97% of PNB-001 bound to rat and human plasma, the amount of free unbound PNB-001 is comparable to some of the marketed drugs. CaCo2 permeability studies indicated that PNB-001 has high permeability and is not effluxed in the B>A direction. This brain penetration is paramount for CNS action without peripheral side effects.
Regulatory toxicology and safety pharmacology studies (acute toxicity studies in rats and mice, 7 day dose range finding studies in rats and dogs, 28 days toxicology studies in rats and dogs, PK studies in rats and dogs, safety pharmacology studies (cardiac, renal, respiratory, and neuro), chromosomal aberration and mutagenesis studies) conducted with PNB-001 under GLP environment and in accordance with ICH guidelines demonstrate extremely high levels of safety and tolerability.
- Synthetic chemistry:
PNB-001 synthetic schema has been established both in non-GMP and in GMP conditions. Moreover, synthetic chemistry efforts are optimized to synthesize PNB-001 one a multi kg scale.
- Phase I clinical trials
Phase I SAD clinical trial protocols had been completed and PNB-001 was found extremely safe over the dose range from 25-1500 mg. A MAD phase 1 clinical trial was also completed for 4 safety groups at low, medium and high doses (50, 100 and 200 mg) and in total PNB-001 is tested now in 74 healthy subjects. Overall PNB-001 was tested very safe and the target plasma concentrations were reached.
- Phase 2 clinical trials
Ulcerative Colitis UC: PNB-001 was previously tested for Lung Inflammation in Covid-19 and was found safe and efficient. Now, PNB-001 was tested in phase 2 for gut inflammation in Ulcerative Colitis and Crohn’s Disease. PNB001 acted again as lymphokine and restore the gut microbiome. 50 and 100 mg adjunct treatment is given to 29 UC and 12 CD patients receiving mesalamine for 28 days 3x daily. For UC stool frequency, rectal bleeding, mucosa appearance and physician assessment was analysed in form of the UCDAI. Mean with SD and response rates were analysed and presented. In the mesalamine treatment group 4 of 9 (44%) subjects responded, compared to 5 of 9 (55%) to 50 mg and 8 of 9 (89%) to 100 mg adjunct treatment with PNB-001. The clinical effect is dose dependent and for mesalamine compared with 100 mg statistically significant with a P value P=0.05. This level of significance was observed for N=9 in only 28 days. PNB-001 was found free from toxicity.
- Intellectual property
Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. Examination by the PTO office in Washington DC did not find any infringement issues with this series of molecules. USPTO has issued the patent on December 28, 2014.
An Inflammation –immune user patent was filed in 2021 and will have patent protection until 2041. User patients for CNS, metabolism and cancer are in preparation and will be filed in year 17 of the original patent.
About PNB-001
Clinical · Phase 1 and Phase 2 completed
The front runner of the portfolio.
Developed from immune-mediated
Inflammatory research, PNB-001 is in Phase 3 for Covid-19 and has completed Phase 2 in Ulcerative Colitis & Crohn's Disease
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
